<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4960">
  <stage>Registered</stage>
  <submitdate>22/12/2014</submitdate>
  <approvaldate>22/12/2014</approvaldate>
  <nctid>NCT02326740</nctid>
  <trial_identification>
    <studytitle>An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>X052173</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pyoderma Gangrenosum</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - gevokizumab
Treatment: drugs - Placebo
Treatment: drugs - gevokizumab open-label

Experimental: gevokizumab - Solution for subcutaneous injection (Part 1, Group B)

Placebo Comparator: Placebo - Solution for subcutaneous injection (Part 1, Group A)

Experimental: gevokizumab open-label - Solution for subcutaneous injection (Part 2, Open-label)


Treatment: drugs: gevokizumab


Treatment: drugs: Placebo


Treatment: drugs: gevokizumab open-label


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later (at Day 140) and without the need for rescue treatment</outcome>
      <timepoint>Day 126</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The proportions of subjects at Day 126 with a reduction in the target ulcer area of = 75% or = 90% from baseline.</outcome>
      <timepoint>Day 126</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  A clinical diagnosis of classic pyoderma gangrenosum

          -  An active pyoderma gangrenosum ulcer

          -  Contraceptive measures adequate to prevent pregnancy during the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Clinical evidence of acutely infected pyoderma gangrenosum

          -  History of allergic or anaphylactic reactions to monoclonal antibodies

          -  History of recurrent or chronic systemic infections

          -  Female subjects who are pregnant, planning to become pregnant, have recently
             delivered, or are breast-feeding

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>9</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital> - Benowa</hospital>
    <hospital> - Woolloongabba</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Fremantle</hospital>
    <hospital> - St. Leonards</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Benowa</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - Fremantle</postcode>
    <postcode> - St. Leonards</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>XOMA (US) LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of
      pyoderma gangrenosum (PG).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02326740</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>